Drug Trial Radar · NCT07223814
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
875
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Jun 2030
Study completion Dec 2033
Sponsor
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- German-Austrian Acute Myeloid Leukemia Study Group
- First posted
- Nov 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this interaction is disrupted in AML with mutations in the NPM1 or KMT2A gene, bleximenib can cause leukemia cells to die. The main objective is to assess if treatment with bleximenib, when added to chemotherapy treatment will improve treatment outcome in adult participants with newly diagnosed AML who present with mutations in the NPM1 or KMT2A genes. This is a randomized, double-blind, placebo-controlled, phase 3 clinical trial. All of the participants will receive standard chemotherapy treatment, combined with either bleximenib or a placebo. A placebo is a substance that looks like the study medicine but has no active ingredients (e.g., a sugar pill). In a double blind trial neither the participant nor the doctor know if placebo or active study drug is given. After the end of the protocol treatment there will be an observational follow-up of 4 years from the time of inclusion of the last patient. The results of the different treatment groups will be compared. 875 previously untreated patients with AML with a specific change in the DNA of the leukemia cells (a KMT2A rearrangement or a NPM1 mutation) will be included. Participants must be 18 years or older and considered eligible for intensive chemotherapy.
Conditions
- Acute Myeloid Leukemia
Interventions
BleximenibDrug
Participants will receive bleximenib
CytarabineDrug
Participants will receive Cytarabine
Daunorubicin or IdarubicinDrug
Participants will receive Daunorubicin or Idarubicin
PlaceboDrug
Participants will receive Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free Survival (EFS) in adult patients with newly diagnosed NPM1m or KMT2Ar AML eligible for intensive chemotherapyTime frame: Up to 4 years and 5 months
Locations
108 sites in 13 countries. Site status is shown where the registry gives one.
US-Los Angeles CA-UCLA
Los Angeles, California · Recruiting
US-San Francisco CA-UCSF
San Francisco, California · Recruiting
US-Orlando FL-ORLANDOHEALTH
Orlando, Florida · Recruiting
US-Atlanta GA-EMORY
Atlanta, Georgia · Recruiting
US-Chigago IL-UHCHICAGO
Chicago, Illinois · Recruiting
US-Kansas City KS-KUMC
Kansas City, Kansas · Recruiting
US-Baltimore MD-UMGCCC
Baltimore, Maryland · Recruiting
US-St Louis MO-WASHU
St Louis, Missouri · Recruiting
US-Charlotte NC-NOVANTCHARLOTTE
Charlotte, North Carolina · Recruiting
US-Winston-Salem NC-NOVANTWINSTON
Winston-Salem, North Carolina · Recruiting
US-Cincinnati OH-CINCY
Cincinnati, Ohio · Recruiting
US-Colombus OH-OSU
Columbus, Ohio · Recruiting
US-Pittsburgh PA-PITT
Pittsburgh, Pennsylvania · Recruiting
AU-Adelaide-FLINDERS
Adelaide, Australia · Recruiting
AU-Adelaide-RAH
Adelaide, Australia · Recruiting
AU-Birtinya-SUNSHINECOAST
Birtinya, Australia · Recruiting
AU-Brisbane-PAH
Brisbane, Australia · Recruiting
AU-Brisbane-RBWH
Brisbane, Australia · Recruiting
AU-Camperdown-RPA
Camperdown, Australia · Recruiting
AU-Melbourne-AUSTIN
Melbourne, Australia · Recruiting
AU-Melbourne-MONASH
Melbourne, Australia · Recruiting
AU-Melbourne-PMCC
Melbourne, Australia · Recruiting
AU-Sydney-RNSH
Sydney, Australia · Recruiting
AU-Sydney-WSAH
Sydney, Australia · Recruiting
AT-Feldkirch-IKHF
Feldkirch, Austria · Recruiting
AT-Linz-ORDENSKLINIKUM
Linz, Austria · Recruiting
BE-Antwerpen-UZA
Antwerp, Belgium · Recruiting
BE-Antwerpen-ZAS
Antwerp, Belgium · Recruiting
BE-Brugge-AZBRUGGE
Bruges, Belgium · Recruiting
BE-Brussel-BORDET
Brussels, Belgium · Recruiting
BE-Bruxelles-STLUC
Brussels, Belgium · Recruiting
Be-Charleroi-GHDC
Charleroi, Belgium · Recruiting
BE-Geel-STDIMPNA
Geel, Belgium · Recruiting
BE-Gent-UZGENT
Ghent, Belgium · Recruiting
BE-Hasselt-VIRGAJESSE (Jessa Ziekenhuis)
Hasselt, Belgium · Recruiting
BE-Haine-Saint-Paul-JOLIMONT
Jolimont, Belgium · Recruiting
BE-Leuven-UZLEUVEN
Leuven, Belgium · Recruiting
BE-Liege-CHULIEGE
Liège, Belgium · Recruiting
BE-Liege-MONTLEGIA
Liège, Belgium · Recruiting
BE-Yvoir-MONTGODINNE
Yvoir, Belgium · Recruiting
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.